NDA 021925 · Takeda Pharms USA
Duetact
Glimepiride, Pioglitazone Hydrochloride · Oral · Sulfonylurea
Last checked: Nov 19, 2026Latest source record: Dec 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jul 28, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
252
102 Phase 3, 1 recruiting
FAERS reports
93
48 serious, 8 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and glimepiride tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . After initiation of pioglitazone and glimepiride tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and glimepiride tablets must be considered [see Warnings and Precautions (5.1) ] . Pioglitazone and glimepiride tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1) ] . Initiation of pioglitazone and glimepiride tablets in patients with established...
What it is approved for
From the label in effect Dec 12, 2025.
Pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies (14) ] . Pioglitazone and glimepiride tablets are a thiazolidinedione and a sulfonylurea combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and glimepiride is appropriate. ( 1 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1 ) Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and glimepiride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions (5.5) ].
Mechanism: Pioglitazone and glimepiride tablets combine 2 antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class, and glimepiride, a member of the sulfonylurea class. Thiazolidinediones are insulin-sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas sulfonylureas are insulin secretagogues that act primarily by stimulating release of insulin from functioning pancreatic beta cells. Pioglitazone Pioglitazone is a thiazolidinedione that depends on...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2016 Supplement 16 · Efficacy Letter
- Jul 28, 2006 Original approval · Type 4 - New Combination ReviewOther Important Information from FDALetter
2 products under this application
- DUETACT · GLIMEPIRIDE 4MG; PIOGLITAZONE HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
- DUETACT · GLIMEPIRIDE 2MG; PIOGLITAZONE HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Glimepiride" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01243424 · 6,103 participants · Start Nov 11, 2010 · Primary completion Aug 21, 2018
Drug: linagliptin; glimepiride and 2 more · For: Diabetes Mellitus, Type 2
Sites: Athens, Alabama; Birmingham, Alabama; Mobile, Alabama · 613 sites in all
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01709305 · 5,570 participants · Start Nov 8, 2012 · Primary completion Apr 17, 2015
Drug: Metformin; Sitagliptin and 4 more · For: Type 2 Diabetes Mellitus
- RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00379769 · 4,447 participants · Start Apr 2001 · Primary completion Dec 2008
Drug: Rosiglitazone; Sulfonylurea and 1 more · For: Diabetes Mellitus, Type 2
Sites: Miranda, Australia; Randwick, Australia; Wollongong, Australia · 446 sites in all
- Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention TrialPivotal-lookingStatus unknown
Italian Society of DiabetologyAcademic, hospital or other
NCT00700856 · 3,371 participants (planned) · Start Sep 2008 · Primary completion Dec 2018
Drug: add-on pioglitazone; add-on sulphonylurea · For: Type 2 Diabetes Mellitus; Cardiovascular Disease
Sites: Seriate, Italy; Treviglio, Italy; Lanciano, Italy · 61 sites in all
- Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00106340 · 3,118 participants · Start Mar 2005 · Primary completion May 2008
Drug: vildagliptin; glimepiride and 3 more · For: Diabetes Mellitus, Type 2
Sites: East Hanover, New Jersey; Nuremberg, Germany
- Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3Recruiting
Washington University School of MedicineAcademic, hospital or other
NCT07589387 · 2,800 participants (planned) · Start Feb 14, 2026 · Primary completion Apr 30, 2029
Drug: Metformin; Glimepiride · For: Diabete Mellitus
Sites: Abaji, Nigeria; Abuja, Nigeria; Bwari, Nigeria · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased9
- bladder cancer8
- drug ineffective8
- dyspnoea7
- nausea7
- vomiting6
- depression5
- dizziness5
- flushing5
- malaise5
- anxiety4
- asthenia4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 14 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 16 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 14 |
| 2016 | 7 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
Nathan DM, Lachin JM, Balasubramanyam A, et al. · N Engl J Med 2022 · Comparative Study, Randomized Controlled Trial
- Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Nathan DM, Lachin JM, Bebu I, et al. · N Engl J Med 2022 · Comparative Study, Randomized Controlled Trial
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, et al. · Front Endocrinol (Lausanne) 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Deng M, Wen Y, Yan J, et al. · BMC Med 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.
Luchsinger JA, Rosin SP, Kazemi EJ, et al. · JAMA Intern Med 2025 · Multicenter Study, Randomized Controlled Trial
- Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.
Gao H, Wei Q, Zou A, et al. · Front Endocrinol (Lausanne) 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.